Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thrombocytosis in cancer patients: when more is not better-in fact, the opposite.

Cancer metastasis reviews·2026
Same author

Pharmacological and Pathological Implications of Sigma-1 Receptor in Neurodegenerative Diseases.

Biomedicines·2025
Same author

<i>CASTOR1</i>: A Novel Tumor Suppressor Linking mTORC1 and KRAS Pathways in Tumorigenesis and Resistance to KRAS-Targeted Therapies in Non-Small Cell Lung Cancer.

bioRxiv : the preprint server for biology·2025
Same author

Tissue factor pathway inhibitor-2 (TFPI-2)-an underappreciated partaker in cancer and metastasis.

Cancer metastasis reviews·2024
Same author

TMEM97/Sigma 2 Receptor Increases Estrogen Receptor α Activity in Promoting Breast Cancer Cell Growth.

Cancers·2023
Same author

The Complex Role of Thrombin in Cancer and Metastasis: Focus on Interactions with the Immune System.

Seminars in thrombosis and hemostasis·2023

Related Experiment Video

Updated: Jun 28, 2026

Prostaglandin Extraction and Analysis in Caenorhabditis elegans
08:50

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Published on: June 25, 2013

Cyclooxygenases, prostanoids, and tumor progression.

Man-Tzu Wang1, Kenneth V Honn, Daotai Nie

  • 1Department of Medical Microbiology, Immunology, and Cell Biology, Southern Illinois University School of Medicine and Cancer Institute, PO Box 19626, Springfield, IL 62794-9626, USA.

Cancer Metastasis Reviews
|September 4, 2007
PubMed
Summary

Prostaglandins, crucial molecules in biological processes, are implicated in cancer progression and metastasis. Targeting prostanoid synthetic enzymes and their receptors offers a potential strategy to impede tumor growth.

More Related Videos

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
07:39

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues

Published on: June 16, 2018

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures
08:02

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures

Published on: July 27, 2022

Related Experiment Videos

Last Updated: Jun 28, 2026

Prostaglandin Extraction and Analysis in Caenorhabditis elegans
08:50

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Published on: June 25, 2013

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
07:39

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues

Published on: June 16, 2018

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures
08:02

Phospholipid Mediator Induced Transformation in Three-Dimensional Cultures

Published on: July 27, 2022

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Arachidonic acid is converted into bioactive eicosanoids via cyclooxygenase (COX), lipoxygenase (LOX), or P-450 epoxygenase pathways.
  • Prostanoids, including prostaglandins and thromboxanes, are key mediators in various biological functions.
  • Aberrant expression of prostanoid synthetic enzymes is increasingly recognized in cancer development.

Purpose of the Study:

  • To review the aberrant expression and functions of prostanoid synthetic enzymes in cancer.
  • To discuss the role of prostaglandins and their receptors in regulating tumor progression and metastasis.
  • To explore targeting prostanoid pathways as a potential anti-cancer strategy.

Main Methods:

  • Literature review focusing on prostanoid synthesis and cancer.
  • Analysis of studies investigating cyclooxygenase (COX) and prostaglandin E2 (PGE2) synthase in tumor progression.
  • Examination of research on prostaglandin receptors (EPs) and their signaling in cancer.

Main Results:

  • Cyclooxygenase-2 (COX-2) and PGE2 synthase are frequently overexpressed in various cancers.
  • Prostaglandin E2 (PGE2) promotes tumor progression by stimulating angiogenesis and other signaling pathways.
  • Prostanoids and their receptors play significant roles in different stages of cancer metastasis.

Conclusions:

  • Targeting prostanoid synthesis or signaling pathways presents a promising therapeutic avenue for cancer treatment.
  • Understanding the specific roles of different prostanoids and their enzymes is crucial for developing effective anti-cancer strategies.
  • Further research into prostaglandin-mediated mechanisms in cancer could lead to novel drug development.